Nature Communications (Sep 2020)
Repurposing anti-inflammasome NRTIs for improving insulin sensitivity and reducing type 2 diabetes development
- Jayakrishna Ambati,
- Joseph Magagnoli,
- Hannah Leung,
- Shao-bin Wang,
- Chris A. Andrews,
- Dongxu Fu,
- Akshat Pandey,
- Srabani Sahu,
- Siddharth Narendran,
- Shuichiro Hirahara,
- Shinichi Fukuda,
- Jian Sun,
- Lekha Pandya,
- Meenakshi Ambati,
- Felipe Pereira,
- Akhil Varshney,
- Tammy Cummings,
- James W. Hardin,
- Babatunde Edun,
- Charles L. Bennett,
- Kameshwari Ambati,
- Benjamin J. Fowler,
- Nagaraj Kerur,
- Christian Röver,
- Norbert Leitinger,
- Brian C. Werner,
- Joshua D. Stein,
- S. Scott Sutton,
- Bradley D. Gelfand
Affiliations
- Jayakrishna Ambati
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Joseph Magagnoli
- Dorn Research Institute, Columbia VA Health Care System
- Hannah Leung
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Shao-bin Wang
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Chris A. Andrews
- Department of Ophthalmology and Visual Sciences, University of Michigan Medical School
- Dongxu Fu
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Akshat Pandey
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Srabani Sahu
- Department of Pharmacology, University of Virginia School of Medicine
- Siddharth Narendran
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Shuichiro Hirahara
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Shinichi Fukuda
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Jian Sun
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Lekha Pandya
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Meenakshi Ambati
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Felipe Pereira
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Akhil Varshney
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Tammy Cummings
- Dorn Research Institute, Columbia VA Health Care System
- James W. Hardin
- Department of Epidemiology & Biostatistics, University of South Carolina
- Babatunde Edun
- Dorn Research Institute, Columbia VA Health Care System
- Charles L. Bennett
- Dorn Research Institute, Columbia VA Health Care System
- Kameshwari Ambati
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Benjamin J. Fowler
- Department of Ophthalmology and Visual Sciences, University of Kentucky
- Nagaraj Kerur
- Center for Advanced Vision Science, University of Virginia School of Medicine
- Christian Röver
- Department of Medical Statistics, University Medical Center Göttingen
- Norbert Leitinger
- Department of Pharmacology, University of Virginia School of Medicine
- Brian C. Werner
- Department of Orthopaedics, University of Virginia School of Medicine
- Joshua D. Stein
- Department of Clinical Pharmacy & Outcomes Sciences, College of Pharmacy, University of South Carolina
- S. Scott Sutton
- Dorn Research Institute, Columbia VA Health Care System
- Bradley D. Gelfand
- Center for Advanced Vision Science, University of Virginia School of Medicine
- DOI
- https://doi.org/10.1038/s41467-020-18528-z
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Inflammasome activation may contribute to type 2 diabetes, but whether targeting inflammasome is beneficial is unclear. Here the authors show that repurposing nucleoside reverse transcriptase inhibitors for inhibiting inflammasome activation is associated with reduced diabetes development in people and improves insulin sensitivity in experimental settings.
